China’s Biopharma Breakout: From Licensing Deals to Global Drug Brands

China’s pharmaceutical industry is no longer defined only by domestic scale or generic-drug manufacturing. Chinese companies are increasingly exporting novel medicines, development platforms and commercial capabilities through three connected routes: licensing assets to multinational drugmakers, creating separately financed international ventures—often known as NewCos—and selling China-developed products directly in overseas markets.

The strongest evidence is the deal market. Chinese companies completed 81 innovative-drug out-licensing agreements in the first half of 2026, with a combined potential value of about $110 billion. That was a record for a six-month period and equivalent to roughly 80% of the comparable full-year total for 2025. Chinese companies also accounted for eight of the 10 largest pharmaceutical out-licensing deals globally during the period.

The deal boom marks a change in how Chinese innovation is valued

Out-licensing is the fastest way for a drugmaker to reach global markets without building a complete international commercial organization. A multinational partner typically brings regulatory expertise, clinical-development resources, market-access teams and sales infrastructure, while the Chinese originator receives upfront payments, milestone opportunities and—in some agreements—royalties or retained rights.

The scale of recent transactions suggests that international buyers are evaluating Chinese companies for the quality of their pipelines, not simply for lower development costs. Reuters reported that the average deal size had reached about $1.3 billion by February 2026, 76% above 2025 levels and roughly six times the average in 2021. The programs attracting interest span areas including oncology, obesity and other metabolic diseases, immunology and neuroscience.

CSPC Pharmaceutical Group’s agreement with AstraZeneca is a prominent example. The collaboration covers eight long-acting peptide programs for weight management and type 2 diabetes and carries potential payments of up to $18.5 billion. The agreement includes an upfront payment, with additional value tied to future development, regulatory and commercial milestones.

That distinction matters. A deal announced at “up to” a particular value is not the same as revenue already received. Industry reporting gives different totals depending on whether a calculation includes all contingent payments, how transactions are counted and whether the focus is on total deal value or upfront payments. One report put first-half outbound business-development value at $99.7 billion and upfront payments at about $5 billion. The headline numbers therefore show the market’s expectations for future assets, not a guaranteed $110 billion cash inflow.

Why NewCo structures are gaining attention

A conventional license transfers rights for a defined territory, product or program to an outside partner. A NewCo structure takes a different approach: an asset or platform is placed into a separately financed company designed to develop and commercialize it internationally.

For Chinese innovators, this model can preserve greater long-term participation in an asset while attracting overseas capital, international governance and development expertise. It can also create a cleaner vehicle for future fundraising, partnerships or a strategic sale. For investors and global pharmaceutical companies, a NewCo may offer more direct exposure to a focused program than a broad partnership with a parent company.

The trade-off is risk. A NewCo must raise enough capital to finance expensive clinical trials and regulatory work. Its founders may give up some control, and its success depends on reaching development milestones before funding runs out. The structure can improve flexibility, but it does not remove the scientific, regulatory or commercial uncertainty inherent in drug development.

Direct commercialization is the more demanding test

Licensing can validate a molecule or platform, but it often leaves the foreign partner with much of the downstream commercial learning. Direct commercialization is harder: the originator must manage approvals, pricing and reimbursement, medical affairs, manufacturing quality, pharmacovigilance, intellectual-property protection and relationships with physicians and health systems across multiple markets.

BeOne Medicines’ Brukinsa illustrates what success on this route can look like. The China-developed blood-cancer treatment generated $3.9 billion in global sales in 2025 and was approved in more than 75 markets, including the United States, Europe, Japan, Korea and Brazil.

The momentum continued in the second quarter of 2026, when Brukinsa recorded $1.2 billion in global sales, including $893 million in the United States. Those results show the value of retaining global commercial rights: a China-rooted company can build an international product franchise and capture product revenue rather than limiting itself to licensing income.

Brukinsa is an important proof point, not evidence that the entire sector has already mastered global commercialization. One successful product does not establish repeatability across therapeutic areas, companies or markets. The next question is whether more Chinese drugmakers can reproduce that performance with differentiated medicines and durable international brands.

A larger innovation system is supporting the expansion

The deal surge rests on a broader industrial base. China’s biopharma ecosystem now combines substantial research investment with domestic manufacturing capacity, contract research and development services, specialist suppliers, large patient populations and an expanding pool of scientific and management talent.

The resulting pipeline is much larger than it was a decade ago. KPMG reported that China-based biotechnology companies accounted for nearly 30% of global drug development as of the first quarter of 2026, with more than 1,200 novel candidates in clinical trials. McKinsey has similarly estimated that China represents about 29% of the global innovative biopharma pipeline.

A larger pipeline creates more opportunities for licensing and partnering, but volume alone is not enough. The commercial value of the ecosystem depends on clinical quality, meaningful differentiation, successful regulatory submissions and medicines that improve outcomes for patients. A deep pipeline increases the odds of producing winners; it does not guarantee them.

Policy is raising biomedicine’s strategic importance

Government policy is another part of the growth story. Biomedicine has been described in government-policy reporting as an “emerging pillar industry,” reflecting a higher strategic status for the sector.

The intended effect is to support more of the innovation chain—from research and clinical trials through approval, manufacturing and use—rather than focusing on a single stage. That kind of support can strengthen infrastructure, attract capital and improve coordination among companies, hospitals, universities and specialist service providers.

The practical impact should still be assessed through implementation. Policy designation by itself does not determine whether companies will receive effective funding, faster approvals, better reimbursement access or stronger incentives for basic research. Those outcomes will be more useful measures of the policy’s success than the label alone.

The remaining hurdles are global execution and original science

The sector’s central challenge is converting research strength into repeatable overseas revenue. Chinese companies may be able to discover and test candidates quickly, but global launches require capabilities that take years to build:

• regulatory strategy in the United States, Europe and other major markets;
• clinical-development programs that satisfy international regulators and physicians;
• pricing, reimbursement and market-access expertise;
• local medical-affairs and commercial teams;
• reliable manufacturing and quality systems;
• pharmacovigilance and post-market evidence generation; and
• protection of intellectual property across jurisdictions.

A second challenge is the depth of basic research. Fast development, platform technologies and differentiated versions of established approaches can create valuable products, but long-term leadership requires original biology, globally important targets and stronger university–hospital–company translation. The ultimate test will be whether China-originated medicines repeatedly secure global approvals, demonstrate clinically meaningful advantages and generate durable sales.

What the 2026 numbers really show

The 81 deals and roughly $110 billion in potential value are best understood as a market signal: multinational companies are increasingly willing to place capital and development responsibility behind Chinese-originated drug assets. The CSPC–AstraZeneca transaction shows how early-stage platforms can attract global interest, while Brukinsa demonstrates the higher-value possibility of taking a China-developed medicine all the way to international patients and revenue.

But the numbers are not yet proof that China has completed its transition into a global pharmaceutical leader. They measure confidence in a growing pipeline and business-development capability. Sustained leadership will depend on what happens after the agreement is signed: which candidates succeed in trials, which products win approval, which companies build effective overseas organizations and which therapies become durable global standards.